CORONA vs VAISHALI: Stock Comparison

Corona Remedies Ltd vs Vaishali Pharma LtdUpdated 25 Aug 26, 4:08 PM ISTNSE & company filings

Corona Remedies Ltd is the larger company by market capitalisation. Corona Remedies Ltd shows a higher ROE, a higher dividend yield and lower leverage, while Vaishali Pharma Ltd shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CORONA leads 7; VAISHALI leads 1 of 8

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CORONAVAISHALI

Valuation lens

What price are you paying?

Market CapContext only
₹12,843 Cr
₹105 Cr
P/E RatioSame reading
66.01x
P/B RatioSame reading
17.59x
EPSCORONA has the higher reading
₹30.3
₹0.32
Book ValueContext only
₹122
₹5.3
Dividend YieldCORONA has the higher reading
0.49%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CORONA is the larger company
₹12,843 Cr vs ₹105 Cr
EPS
CORONA has higher earnings per share
₹30.3 vs ₹0.32
Dividend Yield
CORONA has a higher dividend yield
0.49% vs 0%
Revenue Growth (TTM YoY)
VAISHALI has faster revenue growth
18.35% vs 0%
EPS Growth (TTM YoY)
CORONA has faster EPS growth
0% vs -76.71%
ROE
CORONA has a higher ROE
29.5% vs 6.02%
Net Margin
CORONA has a higher net margin
13.19% vs 3.83%
Operating Margin
CORONA has a higher operating margin
21% vs 3.78%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCORONAVAISHALI
SectorHealthcare
IndustryPharmaceuticals

Price

MetricCORONAVAISHALI
Live Price₹2,097.3₹7.97
Day Change-2.41%-1.85%
Volume14,19393,607
52-Week High₹2,270.1₹12.75
52-Week Low₹1,336.6₹4.75
Distance from 52W High-7.61%-37.49%

Valuation

MetricCORONAVAISHALI
Market Cap₹12,843 Cr₹105 Cr
P/E Ratio66.01x
P/B Ratio17.59x
EPS₹30.3₹0.32
Book Value₹122₹5.3
Dividend Yield0.49%0%

Growth

MetricCORONAVAISHALI
Revenue Growth (TTM YoY)0%18.35%
EPS Growth (TTM YoY)0%-76.71%
Qtr Sales Growth20.2%
Qtr Profit Growth43.7%

Profitability & Leverage

MetricCORONAVAISHALI
ROE29.5%6.02%
ROCE33.3%
Net Margin13.19%3.83%
Operating Margin21%3.78%
Debt to Equity0.22x0.27x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCORONAVAISHALI
Promoter Holding69%31.61%
FII Holding3.63% 1.38 pp0%
DII Holding12.9% 5.88 pp0%
Public Holding14.48% 7.26 pp68.39%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Corona Remedies Ltd and Vaishali Pharma Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.